ETON — Eton Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1710340 ·
Last close
$48.13
Market Cap
$1.32B
52W High
$50.18
52W Low
$23.33
ADV30
520,616
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 24,266,000 | 14,735,000 | 2,414,000 | 1,554,000 | 97,710,000 | 19,661,000 | 67,095,000 |
| Dec 2025 | 21,281,000 | 13,100,000 | 2,464,000 | 1,483,000 | 92,114,000 | 25,942,000 | 65,960,000 |
| Sep 2025 | 22,459,000 | 7,855,000 | -1,363,000 | -1,927,000 | 104,510,000 | 37,121,000 | 81,384,000 |
| Jun 2025 | 18,928,000 | 11,924,000 | -1,475,000 | -2,585,000 | 101,676,000 | 25,379,000 | 77,715,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$15,839,000
Investing CF
$-15,408,000
Financing CF
$1,810,000
CapEx
$-23,256,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.07
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-110,940,000
Inventory
$14,467,000
Receivables
$13,408,000
ST Investments
—
EBIT TTM
$2,040,000
Pretax Income TTM
$-1,486,000
Interest Exp TTM
$3,504,000
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$86,934,000
EBITDA
$11,085,000
Free Cash Flow
$2,438,625
Enterprise Value
$1,354,648,320
Total Cash
$19,661,000
Total Debt
$31,262,000
Shares Out
27,392,358
Trailing EPS
$-0.06
Book Value
$1.12
ROE
-5.4%
ROA
4.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 79,950,000 | -844,000 | -4,601,000 | 92,114,000 | 65,960,000 | — | 10,524,000 |
| Dec 2024 | 39,011,000 | -2,597,000 | -3,823,000 | 76,123,000 | 51,695,000 | — | 969,000 |
| Dec 2023 | 31,642,000 | -1,192,000 | -936,000 | 31,740,000 | 16,263,000 | — | 6,815,000 |
| Dec 2022 | 21,251,000 | -8,260,000 | -9,021,000 | 25,030,000 | 11,952,000 | — | 4,821,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$2.18
Max Pain — expiry 2026-08-21
max pain strike: $35.00 · spot: $46.42 · call oi: 1,941 · put oi: 322
Expected Move to 2026-08-21:
±$7.33
(15.78%) —
implied range
$39.09 –
$53.74
· ATM straddle on $45.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AVLN | Avalyn Pharma Inc. | $1.25B | $28.10 | — |
| AVBP | ArriVent BioPharma, Inc. | $1.40B | $30.04 | — |
| ARDX | ARDELYX, INC. | $1.24B | $5.00 | — |
| HROW | HARROW, INC. | $1.44B | $38.68 | — |
| PRGO | PERRIGO Co plc | $1.44B | $10.43 | — |
News headlines (Yahoo Finance, 1h cache)
Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI® (hydrocortisone) Oral Solution
2026-07-29 10:50 · Yahoo
ETON Stock Jumps 10%: Why Does This Analyst See 47% Upside To Stock?
2026-07-28 16:46 · Yahoo
Eton Pharmaceuticals (ETON) Moves 13.8% Higher: Will This Strength Last?
2026-07-20 11:26 · Yahoo
Apple upgraded, Brinker initiated: Wall Street's top analyst calls
2026-07-17 13:41 · Yahoo
H.C. Wainwright Remains Bullish on Eton Pharmaceuticals’ (ETON) Growth Strategy
2026-05-23 12:16 · Yahoo
Stock Market Leaders Respect The 21-Day Line. You Should Too.
2026-05-22 14:32 · Yahoo
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)
2026-05-19 20:30 · Yahoo
Eton Pharmaceuticals, Inc. Just Missed EPS By 44%: Here's What Analysts Think Will Happen Next
2026-05-16 14:33 · Yahoo
Eton (ETON) Q1 2026 Earnings Call Transcript
2026-05-15 17:21 · Yahoo
Eton Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
2026-05-15 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.